ReShape Lifesciences shares are trading higher after the company announced it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.
Portfolio Pulse from Benzinga Newsdesk
ReShape Lifesciences Inc. has received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX, causing its shares to trade higher.
December 12, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ReShape Lifesciences Inc.'s stock is expected to experience a positive short term impact due to FDA approval for its Lap-Band 2.0 FLEX.
FDA approvals are significant milestones for medical device companies, often leading to increased investor confidence and potential sales growth. The approval of the Lap-Band 2.0 FLEX is likely to be viewed positively by the market, thus driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100